Aliase: 1-(4-methoxypheny)-7-0xo-6-[4-(2-oxopiperidin-1-yl)pheny]-4. 5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
Purity: 99%%min
Appearance:Contact serena for details
Hot selling: EXW price in stock
Usage: Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit,
respectively.
*The following content is generated by AI and is for reference only.
Apixaban, marketed under the brand name Eliquis among others, is a potent and selective direct oral anticoagulant. Chemically known as (3R,4R)-3-[2-oxo-1-(2-pyridinyl)ethyl]-4-(3-methylphenyl)piperazine-1-carboxamide, its molecular formula is C25H28N4O3S. The substance is identified by the CAS number 690903-45-2. Structurally, it functions as a small molecule inhibitor that specifically targets Factor Xa, a critical enzyme in the coagulation cascade. By binding reversibly to the active site of Factor Xa, Apixaban prevents the conversion of prothrombin to thrombin, thereby inhibiting fibrin clot formation without directly affecting platelet aggregation or requiring routine monitoring of blood coagulation parameters like INR.
This medication is primarily indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also widely prescribed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of recurrent DVT and PE following an initial course of therapy. Furthermore, Apixaban plays a crucial role in prophylaxis against venous thromboembolism in patients undergoing hip or knee replacement surgery. Its pharmacokinetic profile offers significant clinical advantages, including predictable pharmacodynamics, rapid onset of action, and no requirement for routine coagulation monitoring. Unlike warfarin, Apixaban has fewer drug-drug interactions and dietary restrictions, making it a preferred choice for many clinicians. While generally safe, common side effects may include bleeding, anemia, and nausea. As with all anticoagulants, careful patient assessment regarding renal function and bleeding risk is essential before initiation. Ongoing research continues to explore its efficacy in various thrombotic conditions, solidifying its position as a cornerstone therapy in modern cardiovascular medicine.